Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women
2024 · New England Journal of Medicine · 373 citations
https://doi.org/10.1056/nejmoa2407001
A
Alexander Kintu
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
22
Papers
1.1K
Citations
11
h-index
12
i10-index
Alexander Kintu is an academic researcher from Gilead Sciences (United States). The author has contributed to research in topics: HIV/AIDS Research and Interventions & HIV/AIDS drug development and treatment & HIV-related health complications and treatments. The author has an h-index of 11, co-authored 19 publications.
ORCID: 0000-0003-3957-1487Papers by this author
worksLong-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial
2021 · The Lancet HIV · 88 citations
https://doi.org/10.1016/s2352-3018(21)00071-0
Cost‐effectiveness analysis of integrating screening and treatment of selected non‐communicable diseases into HIV/AIDS treatment in Uganda
2020 · Journal of the International AIDS Society · 43 citations
https://doi.org/10.1002/jia2.25507
Proximate and distal factors associated with the stall in the decline of adolescent pregnancy in Uganda
2021 · BMC Public Health · 8 citations
https://doi.org/10.1186/s12889-021-11403-6
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat